Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mobile Device Performs Laboratory-Quality HIV Testing

By LabMedica International staff writers
Posted on 21 Feb 2013
A low-cost mobile device has been engineered that combines cell phone and satellite communication technologies with fluid miniaturization techniques and performs all essential enzyme-linked immunosorbent assay (ELISA) functions.

The device combined the portability of mobile technology with the detection potential of enzyme-linked antibodies to create a fully automated and portable microfluidic device dubbed the “mChip,” and has been tested in an African setting. More...


A team of scientists including those at Columbia University (New York, NY, USA) who invented the device assessed its ability to perform serodiagnostic testing for human immunodeficiency virus (HIV) in a field setting and synchronize the results in real time with electronic health records. They tested serum, plasma, and whole blood samples collected in Rwanda and on a commercially available sample panel made of mixed antibody titers.

The handheld apparatus, which is a mobile microfluidic chip for immunoassay on protein markers (mChip) device, captures the essential functions of ELISA as performed by pipetting robots, microplate readers, desktop computers, and communication hardware. The device does not need grid-based power and is sufficiently low in cost and energy consumption to be suitable for resource-limited settings. ELISA is the most sensitive and commonly used laboratory diagnostic for HIV, and historically has taken hours and sometimes days to provide a result. The mChip device, however, produces a result in just 15 minutes.

To explore the performance of the mChip device on coinfected samples, the team evaluated the HIV accuracy of the mChip device on 167 Rwandan patient samples. Also, 100 plasma samples from Rwandan patients were tested for hepatitis B and C (HBV and HCV), as well as 67 serum samples from patients who were also tested for syphilis and herpes simplex virus (HSV-2). Despite the high prevalence of viral hepatitis, 99 positive for HBV and/or HCV in the sample set and the substantial number of sexually transmitted infections, 31 positive for syphilis and/or HSV-2, the diagnostic sensitivity of the mChip device was high at 100%, as was the diagnostic specificity at 99%, with only two false positives.

Samuel K. Sia, PhD., a bioengineer and the senior author of the study, referring to the data repository that doctors can access, said, "Now, with a single push of a button, there is automation not only from the sample to the result, but to the synchronization of data to the cloud. This automation is very important because it minimizes user error and user variability. The real power is that one finger prick can give you multiple rapid test results, making it cheaper and more convenient.” The cost of the device is estimated at USD 100. The study was published on January 17, 2013, in the journal Clinical Chemistry.

Related Links:
Columbia University



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.